Search research articles
Contact Us
Filters
Showing results (21-30 of 204) with videos related to
Page
of 21
Sort By:
Translational Lung Cancer Research
|
February 11, 2020
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Amy Lauren Cummings, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Mitotic inhibitors
Edward B Garon, Steven M Dubinett
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 29, 2009
Intracellular signaling molecules
Edward B Garon, Steven M Dubinett
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Maria A Velez, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2019
Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story
Jonathan W Goldman, Edward B Garon
Cancer Journal (Sudbury, Mass.)
|
December 10, 2020
What Is on the Horizon for Novel Immunotherapies in Lung Cancer?
Edward B Garon, Debory Yi Li
Lung Cancer (Amsterdam, Netherlands)
|
June 25, 2025
Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer
Drew Moghanaki, Emily A Cameron, Edward B Garon
Translational Lung Cancer Research
|
March 26, 2015
Expanding options for EGFR targeting in lung cancer
Tina Chou, Richard S Finn, Edward B Garon
Lung Cancer (Amsterdam, Netherlands)
|
December 7, 2020
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL
Edward B Garon, Jong Seok Kim, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Novel drugs--miscellaneous category
Wylie D Hosmer, Steven M Dubinett, Edward B Garon
Page
of 21
Search research articles
Search
Showing results (21-30 of 204) with videos related to
Sort By:
Page
of 21
Translational Lung Cancer Research
|
February 11, 2020
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Amy Lauren Cummings, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Mitotic inhibitors
Edward B Garon, Steven M Dubinett
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 29, 2009
Intracellular signaling molecules
Edward B Garon, Steven M Dubinett
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Maria A Velez, Edward B Garon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2019
Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story
Jonathan W Goldman, Edward B Garon
Cancer Journal (Sudbury, Mass.)
|
December 10, 2020
What Is on the Horizon for Novel Immunotherapies in Lung Cancer?
Edward B Garon, Debory Yi Li
Lung Cancer (Amsterdam, Netherlands)
|
June 25, 2025
Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer
Drew Moghanaki, Emily A Cameron, Edward B Garon
Translational Lung Cancer Research
|
March 26, 2015
Expanding options for EGFR targeting in lung cancer
Tina Chou, Richard S Finn, Edward B Garon
Lung Cancer (Amsterdam, Netherlands)
|
December 7, 2020
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL
Edward B Garon, Jong Seok Kim, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Novel drugs--miscellaneous category
Wylie D Hosmer, Steven M Dubinett, Edward B Garon
Page
of 21